It is well-established that pharmaceutical molecules can have off-target side effects in the body, but as this often leads to new drugs taking longer and costing more to bring to market, should we be taking advantage of these off-target interactions to create drugs directed at multiple targets or disease pathways?
In this feature, we investigate the applications of drug polypharmacology to drug repurposing and aim to discuss the recent advances and challenges facing research into multi-targeting drugs. We hope you enjoy it and encourage you to share any feedback in the comments below or tweeting @RxNetFSG.
From the Journal
Do you work to develop multi-targeted drugs? What challenges are you facing? Join the conversation today on RxNet, Twitter, Facebook or LinkedIn!